Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Ziccum via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2024-07-02 08:30:00
In a Swedish video interview, Ziccum’s CEO Ann Gidner answers questions from analyst Jonathan Furelid on the topic of business dialogues and agreements.
Apart from elaborating on the significance of the recently concluded Feasibility Study Agreement with ReCode Therapeutics, a leader in the booming mRNA field, Ann Gidner also concludes on the successful completion of the first stage of the Big Pharma II Feasibility Study. Furthermore, Ziccum’s CEO underscores the increasing industry-wide interest generated by Ziccum’s technology, LaminarPaceTM, as evidenced by the growing number of leading industry players reaching out to Ziccum.
Please watch the full interview (in Swedish) here: https://youtu.be/-dnOT8oFLHs